Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 80 years old.
• People who have been diagnosed with an advanced or spreading solid tumour (confirmed through a tissue or cell sample), for whom no effective standard treatment is available.
• People whose general physical functioning is rated at a certain level — specifically, a score of 2 or less on a standard scale used by doctors to measure how cancer affects daily activities (confirm with trial site).
• People with a life expectancy of at least 3 months.
• People whose cancer can be measured or tracked, either through scans or specific markers in the blood.
• People whose blood test results at the screening stage meet specific levels for white blood cells, platelets, haemoglobin, liver function, kidney function, and blood clotting (confirm with trial site for exact values).
• People whose heart is pumping at least 50% of its capacity, and whose heart rhythm measurements fall within specific ranges (confirm with trial site).
• Women who could become pregnant must have a negative pregnancy test at screening.
• People who are sexually active and could father or become pregnant must agree to use effective contraception throughout the study and for 90 days after the last dose, or must have had a surgical procedure that prevents pregnancy.
• People who are able to give written informed consent before any trial-related screening begins.

Who may not be able to join:

• People who have received systemic cancer treatments such as chemotherapy, radiation, biological therapies, hormone therapy, targeted therapy, or immunotherapy within the past 3 weeks (with some exceptions for certain specific treatments — confirm with trial site).
• People who have taken part in another clinical trial and received an experimental treatment within the past 4 weeks.
• People with certain gut conditions, such as Crohn's disease, ulcerative colitis, or short gut syndrome, that could affect how the body absorbs the study drug.
• People with uncontrolled fluid build-up in body cavities (confirm with trial site).
• People whose cancer has spread to the brain and is causing symptoms, requires steroid treatment, involves a lesion of 1.5 cm or larger, or shows signs of growth in the past 4 weeks.
• People with serious heart conditions, including significant heart failure, unstable chest pain, irregular heart rhythm, a heart attack in the past 6 months, or a blood clot or pulmonary embolism in the past 3 months.
• People who have risk factors for a specific type of abnormal heart rhythm called QT prolongation, including a personal or family history of long QT syndrome, or who are taking any medication known to cause this (confirm with trial site).
• People with poorly controlled long-term conditions, including diabetes with a blood sugar marker (HbA1c) of 8.5% or higher, poorly controlled high blood pressure, a history of hypertensive emergency or brain swelling from high blood pressure, or hormonal conditions requiring ongoing systemic treatment.
• People currently diagnosed with a lung condition called interstitial pneumonia, or with a history of chronic emphysema, COPD, or tuberculosis.
• People who have needed systemic treatment for an autoimmune disease within the past 2 years (some exceptions apply, such as stable vitiligo, asthma, or thyroid conditions managed with replacement therapy — confirm with trial site).
• People who have an active infection currently requiring antibiotic treatment through a drip (intravenous).
• People known to have HIV infection.
• People with an active hepatitis B infection (as defined by specific blood test results) or active hepatitis C infection (confirm with trial site for exact definitions).
• People known to have syphilis.
• People who have taken steroid medications at a dose equivalent to 10 mg or more of prednisone per day, or other immune-modifying treatments, within the past 14 days.
• People who plan to receive a live vaccine at any point from 4 weeks before the first dose until 6 months after the last dose.
• People who have had major surgery within the past 4 weeks.
• People who have previously had a bone marrow transplant from a donor or a solid organ transplant.
• People with a known history of a psychiatric condition, or alcohol or drug misuse, that could affect their ability to follow the trial requirements.
• People who still have unresolved side effects from previous cancer treatments above a mild level (some exceptions apply, such as hair loss, nerve-related symptoms, or manageable thyroid changes — confirm with trial site).
• People who experienced a severe immune-related side effect (grade 3 or above) during a previous immunotherapy treatment.
• People with a known allergy to either of the study drugs (ILB-2109 or Toripalimab).
• People who are currently pregnant or breastfeeding.
• People whom the trial doctor considers unsuitable for participation for any other reason.

Important: Always verify eligibility with the trial site directly before applying.